RIGHT Foundation

2024 Annual Report

RIGHT Foundation

Table of Contents

*** Click to move the page.**
Hyperlinks are optimized for PC.

Greetings

Chairman
Myoungsei Sohn

Executive Director
Hani Kim

In 2024, the Research Investment for Global Health Technology Foundation (hereafter "RIGHT") continued its unwavering commitment to advancing global health equity, guided by the trust and collaboration of our partners around the world. Over the past year, RIGHT committed KRW 28 billion (~USD 21 million) to support 11 new grants and leveraged approximately KRW 36 billion (~USD 26.2 million) in co-funding from various collaborators.

One of the most meaningful achievements of the year was the regulatory approval of RIGHT-funded products by global authorities. STANDARD G6PD test, currently the only quantitative point-of-care G6PD test, co-developed by SD Biosensor and Program for Appropriate Technology in Health (PATH), received prequalification from the World Health Organization (WHO PQ) on December 18, 2024. This was soon followed by a WHO policy recommendation for its use with respect to malaria treatment involving tafenoquine or primaquine. The test had already been approved in Australia, and its integration into national malaria programs in Brazil and Thailand has connected thousands of people to improved care, helping to prevent relapses of malaria cases and making an impact on public health.

RIGHT's investments also supported critical advancements in AI-powered diagnostics. miLab™, developed by Noul, is an innovative diagnostic platform that uses AI to detect different types of Plasmodium parasites that can cause malaria. In November 2024, miLab™ was registered and listed with the U.S. Food and Drug Administration (FDA). In a significant milestone, following successful field evaluations in Côte d'Ivoire, the government of Benin entered an agreement with Noul for large-scale public procurement to deliver at least 219 miLab™ units over three years. With the government's decision, it is expected that miLab™ will be made accessible equitably within Benin's local public health system and is expected to expand equitable access to essential diagnostics across low- and middle-income countries (LMICs).

In 2024, RIGHT and its partners made real progress toward ensuring access to essential medical countermeasures as global public goods. We're grateful for your support and look forward to continuing this vital work together.

RIGHT 2.0

The RIGHT's strategy for its second business cycle 2024–2028 (to be called "RIGHT 2.0"), was developed throughout the years 2022–2023 in consultation with the RIGHT's Board of Directors.
The intent of the RIGHT 2.0 is to articulate RIGHT's ambition to seize new opportunities for the Republic of Korea to contribute to global health equity based on the lessons from the first business cycle from2018–2023
(to be called "RIGHT 1.0").

*The RIGHT 2.0 Strategy was approved by the RIGHT Foundation Board of Directors in April 2024

Our Vision, Mission and Objectives

Vision

A world where infectious diseases pose no threat to any community

Mission

Alleviate the burden of infectious diseases that disproportionately affect the people in low- and middle-income countries (LMICs)

Strategic Objectives

Strengthen evidence base for product development with local insights

· Learn to reflect the needs of LMICs with LMIC partners
· Let the local context guide the target use case & product characteristics from the start

Develop essential health technologies as global public goods

· Aim for public procurement
· Ensure global access
· Support technology transfer to enable local production

Train work force inmanufacturing essential health technologies

· Support regional-level self-sufficiency in developing essential public health technologies

Core Value

COLLABORATION

- Foster an exchange of knowledge and skills (i.e. co-develop)
- Contribute Korea's strengths in engineering, process optimization, manufacturing

Key Highlight

New Investments

Total of **28** billion KRW

(Approximately 19 million USD)

Committed to support 11 new investments

Total **69** investments

(Approximately 72.7 million USD)

With a total of 107.5 billion KRW committed since 2018 as of December 31, 2024

Key Achievements from the Funded Projects

WHO prequalification (PQ) and policy recommendation of STANDARD G6PD diagnostic test developed by SD Biosensor and PATH

Successful technology transfer of a Schistosomiasis vaccine candidate (Sm-p80) from PAI Life Sciences (USA) to Quratis (Republic of Korea)

Registration of Noul's miLab™ diagnostic platform by the U.S. Food and Drug Administration(FDA)

Successful completion of the first Vaccine Manufacturing Training Award by RIGHT Foundation with 40 trainees from 14 low- and middle-income countries

Investment Portfolio Overview

Committed Funds Each Year

Total Funding Disbursed
KRW
107.3
billion



Achievement in Co-funding Each Year

Total Co-funding Achieved
KRW
314.1
billion



Number of Funded Projects

69
investments

Distribution by Award Type



Distribution by Product Type



* PDA includes PDA, TAA, and BA under the Product Development program.

Cumulative Total Funding Committed Since 2018 Across Disease Areas



1) Pneumonia: Meningitis + Neonatal Sepsis; **2) EDD** (Enteric and Diarrheal diseases): Cholera + Hep A + Rotavirus + Typhoid; **3) Combined:** Hexavalent, Pentavalent Measles-Rubella, Multiple infectious diseases; **4) NTD:** Neglected Tropical Diseases, Chikungunya + Dengue + Leishmaniasis + Schistosomiasis + Onchocerciasis; **5) STIs/AMR:** Sexually transmitted infections + antimicrobial resistance; **6) Pandemic potential:** COVID19 + Influenza; **7) GAS:** Group A Streptococcus; **8) Others:** 4 EGAs and 1 TA not specific to diseases; **9) SFTS:** Severe fever with thrombocytopenia syndrome

Product Development Award

Vaccines and Therapeutics

*Click the project for more details.
Hyperlinks are optimized for PC.

Active
Completed
Terminated

PORTPOILO



Product Development Award

Diagnostics and Digital Health

***Click the project for more details.**
Hyperlinks are optimized for PC.

Active
Completed
Terminated

PORTPOILO

	Early Prototype Development / Analytical Validation	Clinical Validation/ Usability Assessment	Registration / WHO PQ
Dignositics	Instrument-Free Molecular Diagnostic Platform for COVID-19	2nd Generation G6PD Test	
	Mobile Diagnostic Platform for Influenza and SARS-CoV-2		
	POCT for Pyrazinamide (PZA) Susceptibility Testing	POCT for Multidrug-Resistant TB	
	Quantitative POC Test Using mBFP for G6PD Deficiency	POCT for COVID19, Influenza and RSV	
	Rapid Diagnostic Test for Chikungunya Antigen	POCT for Sexually Transmitted Infections and its AMR	
	SurearlySmart Pro COVID-19	Validation of All-in-One Device for Malaria Diagnostics	
	Handheld POCT for Sexually Transmitted Infections	AI-driven All-in-One Diagnostic Platform for Malaria Species Differentiation	
	POCT for Sexually Transmitted Infections	Rapid Diagnostic Test for Malaria Antigen	
	Leishmaniasis RDT Cartridge and Mobile Pocket Analyzer	2nd Generation TB LAM Assay	
	In vitro Diagnostics Test for Severe Fever and Thrombocytopenia Syndrome	Rapid Diagnostic Test for Malaria Detection in Saliva Samples	
	Rapid Diagnostic Test for Both S.Typhi and S.Paratyphi A		
	Rapid Diagnostic Test for Visceral Leishmaniasis Antigen		
Digital Health	AI-Driven Platform for Anti-Tubercular Drug Discovery	Chest X-ray AI for COVID-19	
	Data Platform to Improve Diagnosis of Infectious Diseases		
	ICT Based Self-risk Assessment Platform for COVID-19		

Product Development Award

New Projects

- Non-replicating Protein Nanoparticle-based Rotavirus Vaccine
- Pentavalent Meningococcal Conjugate Vaccine
- POCT for Sexually Transmitted Infections and its AMR
- POCT for Sexually Transmitted Infections
- Rapid Diagnostic Test for Malaria Antigen
- Handheld POCT for Sexually Transmitted Infections
- Technology Transfer of PentavalentMeningitis Conjugate Vaccine
- Novel Cholera Conjugate Vaccine
- Rapid Diagnostic Test for Malaria Detection in Saliva Samples

New Projects

Product Development Award

Vaccines

Non-replicating Protein Nanoparticle-based Rotavirus Vaccine			
Recipient organization / Country	InThera / Republic of Korea		
Collaborator(s) / Country	International Vaccine Institute (IVI) / Republic of Korea. Virginia Tech University / USA		
Target disease	Rotavirus	Countries / Regions served	Low- and Middle-Income Countries
Project duration	26 months	Development stage	Preclinical
Funding amount(KRW)	1,800,000,000	Award Type	Bridging Award

InThera aims to develop a next-generation parenteral rotavirus vaccine (ENC-P[8]/P[6]/P[4] VP8) to address the limitations of current oral rotavirus vaccines (ORVs). While ORVs have reduced severe diarrhea globally, their effectiveness is lower in middle- and high-burden regions, and concerns persist about rare adverse events like intussusception. The ENC VP8 nanoparticle vaccine targets the major circulating human rotavirus genotypes and elicits a superior immune response via intramuscular administration. This novel approach aims to provide higher efficacy and broader protection, particularly in middle-income countries ineligible for Gavi support. By overcoming the challenges of ORVs, this vaccine could greatly reduce rotavirus-related deaths and improve public health outcomes globally.

Vaccines

Pentavalent Meningococcal Conjugate Vaccine			
Recipient organization / Country	Eubiologics / Republic of Korea		
Collaborator(s) / Country	Program for Appropriate Technology in Health (PATH) / USA		
Target disease	Meningitis	Countries / Regions served	Low- and Middle-Income Countries
Project duration	12 months	Development stage	Phase 2, Phase 3, Regulatory approval / WHO PQ
Funding amount(KRW)	4,000,000,000	Award Type	Bridging Award

EuBiologics aims to develop an affordable pentavalent meningococcal vaccine (NmCV-5) to provide broad protection against invasive meningococcal disease. A Phase I trial in South Korea demonstrated strong immunogenicity and safety, with responses comparable to or better than existing vaccines. Meningococcal epidemics threaten the Sub-Saharan African Meningitis Belt, and while a first pentavalent vaccine has been prequalified, Gavi support for non-emergency use will not begin until late 2025. EuBiologics aims to become the second supplier of a WHO PQ NmCV-5 by 2027, ensuring a secure supply and competitive pricing. In a previous RIGHT Foundation grant, EuBiologics and PATH conducted a Phase I trial in South Korea. Based on the results, Phase II cohorts will be enrolled, and interim safety and immunogenicity data will be used to guide the subsequent enrollment of Phase III cohorts in younger age groups. Phase II cohorts will be enrolled, and interim safety and immunogenicity data will inform subsequent enrollment in Phase III cohorts in younger age groups.

New Projects

Product Development Award

Diagnostics

POCT for Sexually Transmitted Infections and its AMR			
Recipient organization / Country	SD Biosensor / Republic of Korea		
Collaborator(s) / Country	Dankook University Cheonan Campus Industry-Academic Cooperation Foundation / Republic of Korea		
Target disease	Sexually transmitted infections/AMR	Countries / Regions served	Malawi, Nigeria, Ghana, Ethiopia
Project duration	36 months	Development stage	Early Validation, Late Validation, Approval
Funding amount(KRW)	3,999,788,152		

SD Biosensor's STANDARD™ M10 is an innovative molecular diagnostic platform for POC use in decentralized settings. This project develops and evaluates M10's performance using RT-PCR to detect Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and NG-Antimicrobial resistance (AMR). By providing rapid, accurate on-site results, the system enhances disease identification, particularly with inconclusive clinical signs, supporting informed medical decisions. The project will generate analytical and clinical performance data for the CT/NG/NG-AMR cartridge to facilitate registration with stringent regulatory authorities. It includes validation and establishing differentiated pricing for accessibility across income levels. Implementation of this multiplex diagnostic technology aims to improve clinical management of STIs and AMR nationally and internationally.

Diagnostics

POCT for Sexually Transmitted Infections			
Recipient organization / Country	Kryptos Biotechnologies / USA		
Collaborator(s) / Country	Osang Healthcare / Republic of Korea		
Target disease	Sexually transmitted infections/AMR	Countries / Regions served	Thailand, India, Philippines, Nepal, Guatemala, Ukraine, Costa Rica, Bangladesh
Project duration	17 months	Development stage	Preclinical Validation
Funding amount(KRW)	1,778,331,627		

This project focuses on development of a real-time qPCR-based multiplex assay integrated into Kryptos Biotechnologies' existing and portable Kuick platform to simultaneously detect Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis from vaginal swab or urine specimens. The proposal aims to develop the cartridge and optimize the existing platform for the target pathogens, and generate analytical performance data.

Diagnostics

Rapid Diagnostic Test for Malaria Antigen			
Recipient organization / Country	Rapigen / Republic of Korea		
Collaborator(s) / Country	Centro de Pesquisa em Medicina Tropical de Rondônia (CEPEM) / Brazil, Jimma University / Ethiopia		
Target disease	Malaria	Countries / Regions served	World
Project duration	32 months	Development stage	Early Validation
Funding amount(KRW)	903,877,995		

Rapigen has developed a rapid diagnostic test (RDT) for malaria that accurately detects both both Plasmodium falciparum and Plasmodium vivax targeting a protein distinct from the Histidine-rich protein 2 (HRP2). This can address the critical of false-negative results associated with HRP2 deletion in existing RDTs. The project includes clinical validations and a usability study, gathering clinical data that meets WHO PQ criteria through collaborative efforts in Ethiopia and Brazil. The ultimate goal is to submit a WHO PQ dossier for RDTs that detect combined antigens of HRP2 and parasite lactate dehydrogenase (pLDH). Achieving WHO PQ would enable distribution of reliable, high-performance RDTs to LMICs at affordable prices, significantly enhancing malaria detection and treatment, leading to improved health outcomes in endemic regions.

Diagnostics

Handheld POCT for Sexually Transmitted Infections			
Recipient organization / Country	Korea Advanced Institute of Science and Technology (KAIST) / Republic of Korea		
Collaborator(s) / Country	Osang Healthcare, National Nanofab Center (NNFC) / Republic of Korea		
Sexually transmitted infections	Preclinical Validation	Countries / Regions served	Brazil, Philippines, Thailand, Nigeria
Project duration	36 months	Development stage	Preclinical Validation
Funding amount(KRW)	2,160,000,000		

KAIST is developing an ultrafast, low-cost qPCR platform to address STI underdiagnosis in LMICs. Conventional PCR tests are expensive, slow, and require advanced labs, limiting access to timely treatment and increasing risks of infertility, pregnancy complications, and HIV susceptibility. The platform integrates a palm-sized qPCR machine with ultrafast nanoplasmonic thermocycling, real-time fluorescence quantification, and a disposable metal-on-plastic cartridge for extraction-free testing. If proven, this system can deliver significantly improving accessibility and affordability of STI diagnostics. With over one million STIs acquired daily and a high disease burden in LMICs, this rapid point-of-care solution enables early detection and treatment, helping lower STI-related Disability Adjusted Life Years (DALYs) improve reproductive health outcomes, and enhance global STI management.

New Projects

Product Development Award

Vaccines

Technology Transfer of Pentavalent Meningitis Conjugate Vaccine			
Recipient organization / Country	The Biologicals and Vaccines Institute of Southern Africa (Biovac) / South Africa		
Collaborator(s) / Country	EuBiologics / Republic of Korea		
Target disease	Meningitis	Countries / Regions served	Low- and Middle-Income Countries, Sub-Saharan Africa
Project duration	36 months	Development stage	Regulatory Approval / WHO PQ
Funding amount(KRW)	4,000,000,000		

Biovac aims to establish secure, affordable manufacturing of NmCV-5 to eliminate meningococcal disease in Sub-Saharan Africa. Through technology transfer from EuBiologics, Biovac will obtain WHO PQ for a fully liquid NmCV-5, including serogroup X, ensuring sustainable supply for routine immunization and reactive vaccination campaigns. By becoming a priority supplier, Biovac will improve vaccine accessibility at competitive pricing, aligning with the Defeating Meningitis by 2030 Global Road Map. While MenAfriVac eliminated serogroup A, outbreaks due to serogroups C, W, and X persist, requiring a broader solution. Though SIIPL's NmCV-5 is prequalified, additional low-cost, multivalent vaccines are essential for supply stability. With a target price of ≤ $3 per dose, Biovac's NmCV-5 will enhance public health impact by expanding meningitis prevention across Africa.

Vaccines

Novel Cholera Conjugate Vaccine			
Recipient organization / Country	International Vaccine Institute (IVI) / Republic of Korea		
Collaborator(s) / Country	EuBiologics / Republic of Korea, Massachusetts General Hospital / USA		
Target disease	Cholera	Countries/Regions served	Sub-Saharan Africa
Project duration	36 months	Development stage	Phase 2
Funding amount(KRW)	3,999,909,800	Award Type	Bridging Award

Building on the successful Phase I clinical trial funded by RIGHT Foundation that confirmed safety and promising immunogenicity of the Cholera Conjugate Vaccine (CCV), the International Vaccine Institute (IVI) has secured a Bridging Award to advance to Phase II studies. This next phase will produce clinical trial materials and conduct studies in endemic populations, focusing on determining optimal dosing, formulation (with or without adjuvant), and schedules for adults and children through an age-descending approach. By leveraging polysaccharide conjugation technology, CCV aims to deliver higher efficacy, longer-lasting protection, and potential integration into routine childhood immunization programs (EPI). The Phase II trials will specifically evaluate single versus two-dose regimens and explore prime-boost combinations with OCV in children under five. This breakthrough vaccine could significantly reduce cholera burden globally by offering a more effective, programmatically suitable alternative to current interventions, potentially transforming cholera control strategies worldwide.

Diagnostics

Rapid Diagnostic Test for Malaria Detection in Saliva Samples			
Recipient organization / Country	Bernhard Nocht Institute for Tropical Medicine (BNITM) / Germany		
Collaborator(s) / Country	Aarhus University / Denmark, Genes Laboratories / Republic of Korea, GC Labs / Republic of Korea, VPCIR Biosciences / Denmark, Foundation for Innovative New Diagnostics (FIND) / Switzerland		
Target disease	Malaria	Countries / Regions served	Gabon, Germany, Denmark, South Korea
Project duration	36 months	Development stage	Preclinical Validation, Clinical Validation/Utility
Funding amount(KRW)	3,963,890,231		

BNITM aims to develop a novel, non-blood-based malaria diagnostic test to overcome limitations of blood sampling. The prototype Lateral Flow test will use Plasmodium Topoisomerase 1 (pTOP1) as a biomarker, offering improved sensitivity over existing rapid tests while maintaining simplicity for home and field use. Clinical validation will occur primarily in Gabon, Benin, and South Korea, with potential expansion to Ghana, Kenya, and Mozambique. Malaria remains a major global burden, with 247 million cases and 619,000 deaths in 2021, disproportionately affecting Africa. BNITM's innovative approach provides a reliable, accessible alternative to traditional microscopy, reducing diagnostic barriers in high-risk regions. This rapid test will enhance early detection, support malaria elimination efforts, and improve healthcare access in endemic areas.



Product Development Award

Completed Projects

- Pentavalent Meningococcal Conjugate Vaccine
- Novel Cholera Conjugate Vaccine

Completed Projects

Product Development Award

Vaccines

Pentavalent Meningococcal Conjugate Vaccine			
Recipient organization / Country	Eubiologics / Republic of Korea		
Collaborator(s) / Country	Program for Appropriate Technology in Health (PATH) / USA		
Target disease	Meningitis	Countries/Regions served	Sub-Saharan Africa
Project duration	21 months	Development stage	Phase 1, Phase 2, Phase 3
Funding amount(KRW)	2,696,033,970		

This grant aims to develop and obtain WHO PQ for an affordable NmCV-5 vaccine for infants through adults, creating a second supplier to enhance supply security and competitive pricing, in line with the Defeating Meningitis by 2030 Global Road Map. EuBiologics' NmCV-5 is expected to provide durable immunity against all five serogroups, offering direct protection and contributing to herd immunity. Key goals include conducting comprehensive Phase II/III clinical trials in Africa to evaluate safety, immunogenicity, and lot-to-lot consistency compared to a licensed multivalent conjugate vaccine for individuals aged 9 months to 29 years. The vaccine is designed for ease of storage, handling, and administration. Countries in the Sub-Saharan African Meningitis Belt will benefit from enhanced supply security and improved affordability. A Phase I study was conducted in South Korea with clinical trial material produced for Phase II/III studies.

Vaccines

Novel Cholera Conjugate Vaccine			
Recipient organization / Country	International Vaccine Institute (IVI) / Republic of Korea		
Collaborator(s) / Country	Massachusetts General Hospital (MGH) / USA		
Target disease	Cholera	Countries/Regions served	Low- and Middle-Income Countries
Project duration	24 months	Development stage	Phase 1
Funding amount(KRW)	2,642,828,555		

This project continues on from the previously awarded grant from development to the production of the cGMP-compliant materials in several formulations for the phase I clinical trial evaluation. This project is a successful case of materializing the technology transfer of a cholera conjugate vaccine (CCV) product from MGH to EuBiologics. The completion of the Phase I first-in-human (FIH) study within this project period will generated key information on product safety and effects of various antigen doses to guide dose selection.

Evidence Generation Award

PORTPOILO

*Click the project for more details.
Hyperlinks are optimized for PC.



Vietnam
Mongolia
Understanding the End-user Perspectives of Implementing TB-CAD in High TB Burden Settings and Improving Fit for Use in Children

Kiribati
Ethiopia
Nepal
Analyzing Digital Solutions for Health System Gaps in Crisis-Affected Areas

Nigeria
Evaluating Digital tools Applicability for Infectious Disease Surveillance in Communities

Mozambique
Evaluating Digital Health Solutions for Laboratory Diagnosis of Endemic and Pandemic Diseases

Vietnam
Quantifying the Added Value of Lunit Software in Advancing TB Elimination Efforts

Uganda
The Impact of Digital Health Technologies on the Delivery of Maternal and Child Health

Malawi
The Public-Health Assessment of Malawi's One Digitized Infrastructure COVID-19 Study

Completed Projects

Evidence Generation Award



Countries / Regions served

The Public-Health Assessment of Malawi's One DigitiZed Infrastructure COVID-19 Study			
Recipient organization / Country	Luke International / Norway		
Collaborator(s) / Country	Public Health Institute of Malawi (PHIM) / Malawi, Mzuzu University / Malawi		
Target disease	COVID-19	Study Area / Country	Malawi
Project duration	12 months	Product type	Digital Health
Funding amount(KRW)	192,051,958		

This study evaluates the effectiveness and impact of digital health tools used during the COVID-19 response, focusing on the national and community levels. At the national level, the study will assess the Malawi COVID Response Digital Solutions/Services Architecture by examining decision-making processes and the varying success levels of its components. This research intends to inform stakeholders on digital tool effectiveness and user experience, including benefits and gaps. The findings will guide implementers and donors on digital health development strategies, with the aim of strengthening disease surveillance and response capabilities.



Countries / Regions served

Evaluating Applicability of Digital tools for Infectious Disease Surveillance in Community			
Recipient organization / Country	College of Medicine, University of Ibadan / Nigeria		
Collaborator(s) / Country	International Vaccine Institute (IVI) / Republic of Korea, Healthstack Solution Limited / Nigeria, Cetre for Disease Control / Nigeria		
Target disease	Not specific to disease	Study Area / Country	Nigeria
Project duration	12 months	Product type	Digital Health
Funding amount(KRW)	198,125,856		

This project aims to evaluate the effectiveness of digital technologies in enhancing the Early Warning, Alert, and Response System for infectious disease surveillance at health facilities and community levels in Nigeria. Focusing on the gaps exposed by the COVID-19 pandemic, this project seeks to assess the usability, learnability, and applicability of digital tools for improving disease surveillance and control efforts in low-resource settings. The project utilizes quantitative and qualitative analyses to explore the challenges and opportunities for digital applications in public health.



Countries / Regions served

Evaluating Digital Health Solutions for Laboratory Diagnosis of Endemic and Pandemic Diseases			
Recipient organization / Country	Instituto Nacional de Saude (INS) / Mozambique		
Collaborator(s) / Country	-		
Target disease	Not specific to disease	Study Area / Country	Mozambique
Project duration	12 months	Product type	Digital Health
Funding amount(KRW)	200,000,000		

This project evaluates the use of digital health tools for laboratory and surveillance programs within primary healthcare throughout Mozambique. Qualitative and quantitative methods will be used to assess digital infrastructure availability, clarify the facilitators and barriers to digital health tool adoption, and identify opportunities for enhancing digital capabilities in health systems. The aim is to leverage digital health tools for real-time data access, aimed at improving clinical decision-making and enhancing outbreak detection.



Countries / Regions served

The Impact of Digital Health Technologies on the Delivery of Maternal and Child Health Services			
Recipient organization / Country	Compelling Works Limited / Uganda		
Collaborator(s) / Country	-		
Target disease	Not specific to disease	Study Area / Country	Uganda
Project duration	12 months	Product type	Digital Health
Funding amount(KRW)	199,999,918		

This is a cross-sectional study utilizing mixed methods to explore the effect of digital technologies on public health outcomes. The study evaluates Family Connect, a MOH-backed digital platform that aims to improve maternal and child health. Outcomes of this assessment will support the development of targeted strategies to improve access to care and health indicators in Uganda.

Training Award

RIGHT Foundation's Vaccine Manufacturing Training

The Training Award for Vaccine Manufacturing addresses inequities in global vaccine access by strengthening regionalized manufacturing capabilities in LMICs. Executed by Korea National Institute for Bioprocessing Research and Training (K-NIBRT) at Yonsei University's Songdo Campus, this comprehensive 8-week program combined 3 weeks of online didactic learning with 5 weeks of hands-on training at K-NIBRT's GMP-compliant facility. The curriculum covered fundamental principles of vaccine manufacturing across various platforms (including mRNA), Good Manufacturing Practices (GMP), quality control, and regulatory requirements. Targeting technical staff from LMICs engaged from along various stages of the vaccine manufacturing process, the program aimed to equip participants with practical skills to contribute to manufacturing capacity in their home countries. In total, 40 participants from 17 institutions across 14 countries completed the course.

Looking ahead, the program is expected to expand its curriculum to include diagnostic device production technologies and regulatory training.

Trainee Profile by Country



Curriculum

Division	Didactic Training	Hands-on Training
Period	Training : May 20 - June 16	July 1 - August 2
Location	Online via LearnUs	K-NIBRT Training Center (85, Songdogwahak-ro, Yeonsu-gu, Incheon)

Didactic Training (3 modules)**: Online via LearnUs** (5/20~6/21)

Module 1	**Basics for Biopharmaceutical and Bioprocess**
Day 1	Introduction to Biopharma Industry
	Biologics Regulation
	Cell and Enzyme
Day 2	Core Technologies of Therapeutic
	Production of Recombinant Proteins in Prokaryotic Hosts
Day 3	Production of Recombinant Proteins in Eukaryotic Cells
	Cell Growth
Day 4	How Vaccines Work
	Vaccine Registration and International Cooperation
Day 5	GMP for Biopharmaceuticals
	QC and Analysis of Biopharmaceuticals
Module 2	**Vaccine Manufacturing Process**
Day 1	Bioprocessing Basics & Aseptic Processing
	Upstream Processing
Day 2	Downstream Processing
	mRNA Medicines & LNP (with Moderna Korea)
Day 3	Vaccine Manufacturing Process: DNA and mRNA
	Formulation (stability and quality control, quality issues for advanced products)
Day 4	Lyophilization (Freeze - drying, unit operation, cycle development, understanding and monitoring process)
	Performance Qualification (PQ) and Process Validation for Vaccine
Day 5	Vaccine Manufacturing Process: Drug Product (DP) (Fill and Finish)
	Recent Trends in Vaccine Research and Development
Module 3	**RA: Regulation of Biopharmaceuticals**
Day 1	Biopharmaceutical Regulatory Affairs (RA) in Korea and Harmonization
	ICH Guidelines
Day 2	CMC (Chemistry, Manufacturing and Control)
	Pharmacopeial and International Collaboration
Day 3	Nonclinical Drug Development
	Accelerated Approval of COVID-19 Vaccine during the Pandemic
Day 4	Clinical Research Industry Trends and International Standards
	Drug Reimbursement and Health Technology Assessment in Korea
Day 5	The Korea Drug Approval-Patent Linkage System
	Post Marketing Surveillance of Pharmaceuticals

Training Award

RIGHT's Vaccine Manufacturing Training: Key Moments in Photos

Opening Ceremony

Hands-On Training


Fermentation


Fermentation


Formulation & Filling


Purification


Preparation


QC & Bioanalytics

Students engaged in hands-on training across key stages of vaccine manufacturing–Fermentation, Purification, Preparation, Formulation & Filling and QC & Bioanalytics.

Completion Ceremony

Other Updates

WORLD BIO SUMMIT 2024

Annual International Forum Successfully Held

RIGHT hosted a forum under the title, "Driving Global Health R&D with End-to-End Approach Toward Equitable Access to Essential Health Technologies" at ConvensiA, Song-do, on Tuesday November 12th.

The forum was a side event of the 2024 World Bio Summit jointly hosted by the Ministry of Health and Welfare and WHO. Among the key participants were delegates from the Ministries of Health and Welfare (MOHW), Science and ICT (MSIT), and Foreign Affairs (MOFA); global funders, namely the Asian Development Bank (ADB), UNITAID, and CEPI ; executive members from the Korean and international life science industry including Bioneer, Eubiologics, LG Chem, Noul, SK bioscience, Shin Poong Pharm. Co., Ltd., and Biovac (South Africa); and leading global health R&D organizations such as PATH, STOP TB, and READDI. With around 150 attendees filling the room, the forum was a huge success.

The forum featured three sessions: (1) Korea's contributions to regional and global health; (2) international partnerships for health equity; and (3) global health R&D investments addressing funders' perspectives. Focused on Korea's contribution to global health, participants in the sessions highlighted collaboration across industrial, governmental, and international community sectors driving efforts to advance global health R&D and equitable access.

Building on the momentum, RIGHT plans to actively engage in international forums in 2025 by organizing dedicated sessions to showcase the RIGHT's initiatives and share Korea's R&D progress on the global stage.

Signed MoUs to Strengthen Global and Domestic Partnerships

RIGHT signed Memoranda of Understanding (MoUs) with international and Korean organizations- UNITAID, ADB, CEPI, GFID, K-Health MIRAE Initiative, and announced plans to seek opportunities for complementary funding with the new partners to ensure that RIGHT's funded products reach global and equitable access and achieve greater impact on global health.

Hani Kim, the Executive Director of RIGHT, stated, "This is a momentous occasion for the RIGHT Foundation. From RIGHT's perspective, it represents the fruit of numerous discussions and shared enthusiasm with each of these partners to drive health R&D towards regional and global public health and health equity. While each of us is distinct from one another, the focus is on our shared value and that is health equity. RIGHT is committed to this shared value, and to contributing Korea's ODA and strengths in R&D to improving regional and global health equity."

Other Updates

Activities to Strengthen Global Partnerships for Global Health

RIGHT is dedicated to expanding its global network and continues to seek opportunities for collaborations with international organizations, governments, and companies.

WHO/MPP mRNA Technology Transfer Programme Follow-Up Meeting: Establishing R&D Consortia

On March 18 and 19, RIGHT presented at the "WHO MPP mRNA Technology Transfer Regional Meeting on Building R&D Collaborations" meeting organized by the WHO and the Medicines Patent Pool (MPP). The objectives of the meeting were to review key considerations for developing a regional mRNA R&D consortium in Asia, reflecting the needs and the capabilities of the region. Discussion particularly focused on developing mRNA vaccines against dengue, hand, foot, and mouth disease, malaria, and human papillomavirus (HPV). RIGHT highlighted its commitment to supporting technology transfer.

World Health Assembly Follow-Up Event; Accelerating Diagnostics Health Innovation for Infectious Disease

RIGHT, together with Permanent Mission of the Republic of Korea in Geneva, and in partnership with UNITAID and STOP TB Partnership, jointly hosted a side event at the World Health Assembly held from May 27 to June 1 with a focus on accelerating diagnostics innovation for infectious diseases. The session moderated by Hoon Sang Lee, the Chief Strategy Officer of RIGHT, attracted experts from various global health funders, PDPs and NGOs, including Global Fund, ADB, MMV and MSF. The discussion emphasized innovative approaches to enhance access to diagnostics for TB and Malaria and affirmed a collective commitment to ensure that research findings translate to an impact on global health. RIGHT highlighted Korea's potential to contribute to closing the global diagnostics gap.

25th Developing Countries Vaccine Manufacturing Network (DCVMN) Annual General Meeting

RIGHT Foundation participated in the 25th DCVMN Annual General Meeting, held from October 15–18, 2024, in São Paulo, Brazil. The event brought together over 350 participants, including representatives from over 40 vaccine manufacturers, international organizations such as WHO, CEPI, and GAVI, as well as global health funders like the Gates Foundation. RIGHT emphasized its commitment to collaborating with other funders to provide an end-to-end support to vaccine development for regional and global public health.

Finances

Assets and Liabilities (Balance Sheet)

(Unit: Million)

2024		
	KRW	USD
Current Assets	30,643	20.85
Non-current Assets	320	0.22
Total Assets	30,963	21.06
Current Liabilities	5,617	3.82
Non-current Liabilities	443	0.30
Total Liabilities	6,060	4.12
Fundamental Net Assets	5	0.00
Common Net Assets	24,899	16.94
Total Equity	24,904	16.94
Total Liabilities and Equity	30,963	21.06

Revenue

(Unit: Million)

	2024		2023	
	KRW	USD	KRW	USD
Fund (Government & Foundation)	16,188	11.01	17,171	11.68
Donation (Industry)	2,750	1.87	2,250	1.53
Others	2,666	1.81	976	0.66
Total Revenue	21,604	14.07	20,397	13.88



2024 Sources of Business Revenue

Expenses

(Unit: Million KRW)

	2024		2023	
	KRW	USD	KRW	USD
Project Expenses	22,911	15.59	16,017	10.90
Operational Expenses	1,935	1.32	1,431	0.97
Other Expenses	166	0.11	199	0.14
Total Expenses	25,012	17.01	17,648	12.01

Yearly Secured Revenue by the Types of Funders

(Unit: Million KRW)



Governance

Council Members

Full Partner

- Korea Disease Control and Prevention Agency National Institute of Health
- Ministry of Health and Welfare
- Gates Foundation
- International Vaccine Institute
- eubiologics
- LG Chem
- SD BIOSENSOR
- SK bioscience

Associate Partner

- BIONEER
- noul
- QuadMedicine

Board of Directors

Myongsei Sohn
Chairman

Hani Kim
Executive Director

Eunyoung Jung
Ex-Officio Member

Dokeun Kim
Ex-Officio Member

Keiji Fukuda
Member at Large

Glenn Rockman
Member at Large

Peter Hotez
Member at Large

Isabel Torres
Ex-Officio Observer

Selection Committee

Ann Mills-Duggan
Chairperson, AMD Biomedical Consulting

Ajoy Chakrabarti
Gates Foundation

Anna-Karin Tidén
Independent Medicinal Chemistry Expert

Melissa Malhame
MM Global Health Consulting LLC

Michael Hawkes
University of British Columbia

Shabir A. Madhi
University of the Witwatersrand, Johannesburg



Betsy Wonderly Trainor
Combat Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X)

Kee-jong Hong
College of Medicine, Gachon University



Lynda Stuart
Fund for Science and Technology

Rinn Song
University of Oxford

Woo Joo Kim
Former Korean University College of Medicine

Grantees & Collaborators

International Partners



Korean Partners

abion
BIONEER
BIONOTE
BIO SQUARE
BoreDa Biotech
가톨릭대학교 The Catholic University of Korea
CHA Vaccine Institute
Chungnam National University
CTCVAC
DAEWOONG THERAPEUTICS INC.
DANKOOK UNIVERSITY
eubiologics
fine healthcare
가천대학교 Gachon University
GC Labs
GenBody Inc. CHANGE AND INNOVATION
Genecell Biotech
Genes Laboratories
Genexine
경북바이오산업연구원 Gyeongbuk Institute for Bio Industry
ImmuneMed
Institut Pasteur Korea
International Tuberculosis Research Center
InThera
JEIL PHARMACEUTICAL CO.,LTD.
JEONBUK NATIONAL UNIVERSITY
KHAV ONE HEALTH
KOLON LIFE SCIENCE
KONKUK UNIVERSITY
KAIST
KBSI KOREA BASIC SCIENCE INSTITUTE
KIT Korea Institute of Toxicology
kt
LG Chem
Lunit
MONITOR
mobile doctor
ModoriC
나노종합기술원 NATIONAL NANOFAB CENTER
noul
OptiBio
OHC OSANG HEALTHCARE
PANGEN BIOTECH
PHILMEDI
PRECISION BIOSENSOR
QuadMedicine
Quratis
RAPHAS
Rapigen
SD BIOSENSOR
SEOUL NATIONAL UNIVERSITY
SNUH 서울대학교병원 SEOUL NATIONAL UNIVERSITY HOSPITAL
SHIN POONG PHARM. CO.,LTD.
SK bioscience
SK biotek
SolGent
Standigm
ST PHARM
SUGENTECH
삼성의자대학교
VUNO
YONSEI UNIVERSITY

RIGHT Foundation

Location
#03145 4F Dongduk Building, 68 Ujeongguk-ro, Jongno-gu, Seoul, Republic of Korea

Contact us
+82-2-6337-9400

Email
Publicrelations@rightfoundation.kr

Website
https://rightfoundation.kr/en/